| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer WP McGuire, WJ Hoskins, MF Brady, PR Kucera, EE Partridge, KY Look, ... New England Journal of Medicine 334 (1), 1-6, 1996 | 3659 | 1996 |
| Incorporation of bevacizumab in the primary treatment of ovarian cancer RA Burger, MF Brady, MA Bookman, GF Fleming, BJ Monk, H Huang, ... New England Journal of Medicine 365 (26), 2473-2483, 2011 | 2889 | 2011 |
| The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma WJ Hoskins, WP McGuire, MF Brady, HD Homesley, WT Creasman, ... American journal of obstetrics and gynecology 170 (4), 974-980, 1994 | 958 | 1994 |
| Prognostic factors in early‐stage uterine sarcoma: a Gynecologic Oncology Group Study FJ Major, JA Blessing, SG Silverberg, CP Morrow, WT Creasman, ... Cancer 71 (S4), 1702-1709, 1993 | 883 | 1993 |
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup MA Bookman, MF Brady, WP McGuire, PG Harper, DS Alberts, ... Journal of clinical oncology 27 (9), 1419-1425, 2009 | 876 | 2009 |
| Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ... New England Journal of Medicine 381 (25), 2403-2415, 2019 | 845 | 2019 |
| Inherited mutations in women with ovarian carcinoma BM Norquist, MI Harrell, MF Brady, T Walsh, MK Lee, S Gulsuner, ... JAMA oncology 2 (4), 482-490, 2016 | 837 | 2016 |
| Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology … FM Muggia, PS Braly, MF Brady, G Sutton, TH Niemann, SL Lentz, ... Journal of Clinical Oncology 18 (1), 106-106, 2000 | 744 | 2000 |
| Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study … RL Coleman, MF Brady, TJ Herzog, P Sabbatini, DK Armstrong, JL Walker, ... The Lancet Oncology 18 (6), 779-791, 2017 | 644 | 2017 |
| Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. GA Omura, MF Brady, HD Homesley, E Yordan, FJ Major, HJ Buchsbaum, ... Journal of clinical oncology 9 (7), 1138-1150, 1991 | 634 | 1991 |
| Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group JT Thigpen, MF Brady, RD Alvarez, MD Adelson, HD Homesley, ... Journal of Clinical Oncology 17 (6), 1736-1736, 1999 | 619 | 1999 |
| Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) KS Tewari, MW Sill, RT Penson, H Huang, LM Ramondetta, LM Landrum, ... The Lancet 390 (10103), 1654-1663, 2017 | 617 | 2017 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 558 | 2005 |
| Secondary surgical cytoreduction for advanced ovarian carcinoma PG Rose, S Nerenstone, MF Brady, D Clarke-Pearson, G Olt, SC Rubin, ... New England Journal of Medicine 351 (24), 2489-2497, 2004 | 530 | 2004 |
| Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study JT Thigpen, MF Brady, HD Homesley, J Malfetano, B DuBeshter, ... Journal of clinical oncology 22 (19), 3902-3908, 2004 | 482 | 2004 |
| Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. GJ Rustin, AE Nelstrop, P McClean, MF Brady, WP McGuire, WJ Hoskins, ... Journal of Clinical Oncology 14 (5), 1545-1551, 1996 | 451 | 1996 |
| Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, ... Journal of Clinical Oncology 37 (26), 2317-2328, 2019 | 440 | 2019 |
| Simultaneously detected endometrial and ovarian carcinomas—a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study R Zaino, C Whitney, MF Brady, K DeGeest, RA Burger, RE Buller Gynecologic oncology 83 (2), 355-362, 2001 | 402 | 2001 |
| Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer JK Chan, MF Brady, RT Penson, H Huang, MJ Birrer, JL Walker, ... New England Journal of Medicine 374 (8), 738-748, 2016 | 394 | 2016 |
| Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study J Bell, MF Brady, RC Young, J Lage, JL Walker, KY Look, GS Rose, ... Gynecologic oncology 102 (3), 432-439, 2006 | 387 | 2006 |
